YANTAI, China, April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented...
Hence then, the article about remegen announces exciting results of telitacicept phase 3 clinical trial for patients with generalized myasthenia gravis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis )
Also on site :
- Inter Miami vs San Diego: When and Where to Watch Messi in MLS 2026
- Humanoid robot sales hit 7,000 worldwide last year
- 50 Years Ago Today, ‘Happy Days’ Unexpectedly Replaced One Of Its Most Beloved Characters—And Things Were Never the Same